What We Fund - National Multiple Sclerosis Society

Skip to navigation Skip to content

What We Fund

Share

In this article

Overview

Developing new treatments for people with MS requires continuing research discovery and knowledge – and driving the commercial development of those findings into treatments. Facilitation of commercial development is the part of the equation Fast Forward focuses on.

Fast Forward deploys an innovative funding model, one that creates availability through both a General Fund as well as a Collaborative Fund approach. This unique model offers a wide range of available funding, on a rolling RFP basis as well as additional, specific RFP cycles.

To learn more about our current funding opportunities, please contact Fast Forward at research@fastforward.org

General Fund

Funding available for neuroprotection and neuroregeneration in multiple sclerosis

The National Multiple Sclerosis Society is committed to being a driving force of MS research and treatment to stop disease progression, restore function, and end MS forever.

As part of its commitment to addressing the needs of individuals affected by progressive forms of MS, the Society invites proposals from commercial organizations to establish research partnerships with Fast Forward to accelerate and support development of therapeutic strategies for protecting the nervous system from damage (neuroprotection) and ways to repair the nervous system to restore function.

Note: Inquiries with Fast Forward staff are required to determine alignment of a proposal with Fast Forward's priorities.

Collaborative Fund

Bringing a new drug to market is not unlike other product challenges – it requires a multitude of participants with unique expertise areas, and the focus and finances to propel it forward. A ground-breaking collaboration between Fast Forward and EMD Serono, Inc., has created a fund that supports two key areas to stimulate development of new MS treatments.

Accelerating Commercial Development Fund: Provides funding opportunities of up to $500,000 annually (direct and indirect costs) to commercial entities for the development of MS treatments. Funding availability is world-wide, and follows an annual RFP cycle.

To learn more about who has already received funding through the Accelerating Commercial Development Fund, click here.

Accelerating Innovation Fund: Provides funding opportunities of up to $250,000 annually (direct and indirect costs) for university-based or seed-stage organizations. Funding availability is world-wide, and follows an annual RFP cycle.

To learn more about who has already received funding through the Accelerating Innovation Fund, click here.

Share

Our Impact

To hear about the impact of Fast Forward, view this brief video from Michael Richman from Amplimmune.